Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Defensin beta 130D (DEFB130D) is a pseudogene in the beta-defensin family, indicated by the "D" suffix that typically denotes non-functional gene copies in gene nomenclature[2]. Unlike functional defensin genes such as DEFB130, DEFB130D does not encode an active antimicrobial peptide and does not participate in immune responses, host defense, or serve as a therapeutic target. If the interest is in an immune effector molecule, the functional gene is Defensin beta 130 (DEFB130), not DEFB130D.\n\nFor reference, the defensin beta family generally consists of small, cationic peptides involved in the innate immune system, with antimicrobial and immunomodulatory activities[1][3][5]. However, this does not apply to DEFB130D, which is genomically present but non-functional. \n\nThe use of DEFB130D as a drug target would be incorrect; research, functional, and therapeutic literature focus on functional beta-defensin genes and their protein products, not pseudogenes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Defensin beta 130D pseudogene (DEFB130D).